Want to see TLSI full AI Analyst Report?
TLSI Stock Chart & Stats
$4.22
$0.10(2.37%)
At close: 4:00 PM EDT
$4.22
$0.10(2.37%)
Day’s Range― - ―
52-Week Range$2.20 - $7.95
Previous Close$4.32
Volume94.41K
Average Volume (3M)399.91K
Market Cap
$343.59M
Enterprise Value$253.39
Total Cash (Recent Filing)$46.29M
Total Debt (Recent Filing)$34.43M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 12, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding61,574,600
10 Day Avg. Volume201,479
30 Day Avg. Volume399,911
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-10.14
Price to Sales (P/S)7.60
P/FCF Ratio-18.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside136.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$52.40M
Bulls Say, Bears Say
Bulls Say
High Revenue Growth And Very High Gross MarginsConsistent ~43% TTM revenue growth paired with mid‑80s gross margins demonstrates durable unit economics for TriNav/PEDD. High margins imply favorable product economics and pricing power; as commercial scale increases these economics can sustainably absorb SG&A and R&D, aiding a path to profitability over time.
Robust Clinical Evidence And Expanding PipelineLandmark RWE and an expanding program (10 active studies, multiple prospective trials) provide structural clinical validation. This durable evidence base supports payer acceptance, physician adoption and broader label/indication expansion, reducing commercial adoption friction and underpinning long‑term market penetration.
Commercial Organization Expansion And Leadership AddedDoubling the salesforce and adding senior commercial leadership creates lasting distribution capability. A scaled commercial org and structured 6–9 month ramp are durable assets that improve territory coverage, sales productivity and feedback loops, supporting sustainable revenue growth as clinical evidence converts to adoption.
Bears Say
Heavy Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow (~-$29M TTM) is a structural concern. Ongoing cash burn forces reliance on external financing, raising dilution and execution risk, and constrains the company's ability to fund trials, manufacturing scale-up, and commercial investment without access to capital markets.
High Leverage And Weakened Equity BaseElevated leverage (debt ~$34M vs equity ~$6.6M) and historical negative equity reduce financial flexibility. High debt burdens increase fixed obligations and limit capacity to absorb shocks, making future R&D and commercialization investments more costly or dependent on dilutive financing, a persistent structural risk.
Regulatory Timing Uncertainty For TriNav AdvanceA multi-month FDA review delay shifts the device commercialization timeline and defers expected revenue. Prolonged regulatory uncertainty hampers planning for manufacturing scale, reimbursement timing and sales ramp, extending dependence on cash reserves and partnerships and creating durable execution risk for 6–18 months.
TriSalus Life Sciences News
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $2.20 and its highest was $7.95 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $343.59M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Nov 12, 2026 which is in 92 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Aug 06, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.005.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.13.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 61,574,600 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went up 15.195%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (136.97% Upside)
$10.00 (136.97% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 109.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
51.14%
Trailing 12-Months
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
TLSI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major clinical and economic validation of PEDD (landmark real-world study, strong pipeline, meaningful early results in multiple new indications) and a deliberate commercial build intended to capture a large addressable market. Near-term financials were impacted by the deliberate salesforce expansion (temporary revenue disruption, higher operating losses) and a regulatory delay for TriNav Advance that defers some expected second-half revenue. Management positions the investments as strategic and funded by a solid cash balance, with expectations of sustained ramp and commercial momentum through the remainder of 2026 and beyond.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$10.00
▲(136.97% Upside)
Technical Analysis
Ownership Overview
28.15% Insiders
6.62% Mutual Funds
2.20% Other Institutional Investors
56.61% Public Companies and
Individual Investors